Literature DB >> 16597510

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

A Doblas1, C Domingo, H G Bae, C L Bohórquez, F de Ory, M Niedrig, D Mora, F J Carrasco, A Tenorio.   

Abstract

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a recently described severe adverse event after yellow fever vaccination, and some cases have been reported in different countries [Anonymous. Effects of yellow fever and vaccination. Lancet 2001;358(9296):1907-9]. Herein we describe a YEL-AVD case in a young woman, who died after vaccination with 17D-204 strain. Clinical, serological and immunochemical analysis as well as virus detection, quantification, sequence analysis and cytokine release, were performed. Further investigations on yellow fever vaccine adverse events, and carefully analysis of the immune response elicited are important tasks for the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597510     DOI: 10.1016/j.jcv.2006.02.005

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  21 in total

1.  NIAID workshop on Flavivirus immunity.

Authors:  Alison D Augustine; M Cristina Cassetti; Francis A Ennis; Eva Harris; William H Hildebrand; Patricia M Repik
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

2.  Detection of yellow fever 17D genome in urine.

Authors:  Cristina Domingo; Sergio Yactayo; Edinam Agbenu; Maurice Demanou; Axel R Schulz; Katjana Daskalow; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

3.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 4.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

5.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

6.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

Review 7.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

8.  Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus.

Authors:  Matthias Niedrig; Oliver Kürsteiner; Christian Herzog; Karen Sonnenberg
Journal:  Clin Vaccine Immunol       Date:  2007-11-28

9.  Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  Mark D Gershman; J Erin Staples; Adwoa D Bentsi-Enchill; J Gabrielle Breugelmans; Glacus S Brito; Luiz Antonio Bastos Camacho; Pascale Cottin; Cristina Domingo; Anna Durbin; Joaquim Gascon; Fouzia Guenaneche; Edward B Hayes; Zsuzsanna Jelenik; Alena Khromava; Reinaldo de Menezes Martins; Mario Masana Wilson; Nathalie Massy; Abdulsalami Nasidi; Matthias Niedrig; Adam Sherwat; Theodore Tsai; Anna Vilella; Mary Elizabeth Wilson; Katrin S Kohl
Journal:  Vaccine       Date:  2012-05-04       Impact factor: 3.641

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.